NCT03974113 - Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

August 15, 2026

Study Completion Date

December 15, 2026

Conditions

Hemophilia

Interventions

DRUG

Fitusiran

Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous

Trial Locations (16)

17033

Penn State Milton S. Hershey Medical Center- Site Number : 8400006, Hershey

20122

Investigational Site Number : 3800001, Milan

28046

Investigational Site Number : 7240002, Madrid

34093

Investigational Site Number : 7920002, Istanbul

44106

University Hospitals of Cleveland- Site Number : 8400007, Cleveland

50134

Investigational Site Number : 3800002, Florence

90027

Children's Hospital Los Angeles Site Number : 8400002, Los Angeles

560034

Investigational Site Number : 3560006, Bangalore

632004

Investigational Site Number : 3560004, Vellore

07601

Hackensack University Medical Center- Site Number : 8400008, Hackensack

L8N 3Z5

Investigational Site Number : 1240001, Hamilton

K1H 8L1

Investigational Site Number : 1240002, Ottawa

400 022

Investigational Site Number : 3560002, Mumbai

411 011

Investigational Site Number : 3560001, Pune-411011

01130

Investigational Site Number : 7920001, Adana

TR-35100

Investigational Site Number : 7920003, Izmir

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY